UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: further results from the prospective PANTHER study with focus on obese patients

Annals of oncology, 2019-01, Vol.30 (1), p.109-114

2019

Volltextzugriff (PDF)

Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial

Annals of oncology, 2006-02, Vol.17 (2), p.289-296

2006

Volltextzugriff (PDF)

Phase II Genomics Study of Ixabepilone as Neoadjuvant Treatment for Breast Cancer

Journal of clinical oncology, 2009-02, Vol.27 (4), p.526-534

2009

Volltextzugriff (PDF)

Abstract P6-21-02: Withdrawn

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P6-P6-21-02

2019

Volltextzugriff (PDF)

Tailored dose-dense chemotherapy in combination with trastuzumab as adjuvant therapy for HER2-positive breast cancer: A secondary analysis of the phase III PANTHER trial

JOURNAL OF CLINICAL ONCOLOGY, 2019, Vol.37 (15_suppl), p.553-553

2019

Volltextzugriff (PDF)

Dose tailoring of breast cancer adjuvant chemotherapy aiming at avoiding both over and undertreatment: Results from the prospective PANTHER study

JOURNAL OF CLINICAL ONCOLOGY, 2018, Vol.36 (15_suppl), p.538-538

2018

Volltextzugriff (PDF)

Adjuvant denosumab in early breast cancer: Disease-free survival analysis of 3,425 postmenopausal patients in the ABCSG-18 trial

JOURNAL OF CLINICAL ONCOLOGY, 2018, Vol.36 (15_suppl), p.500-500

2018

Volltextzugriff (PDF)

Abstract P1-09-10: Pathological complete response to neoadjuvant trastuzumab is dependent on HER2/CEP17 ratio in HER2-amplified early breast cancer

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P1-P1-09-10

2017

Volltextzugriff (PDF)

Abstract P4-22-20: Efficacy and safety of everolimus plus exemestane in HR+, HER2– advanced breast cancer progressing on/after prior endocrine therapy, in routine clinical practice: 2nd interim analysis from STEPAUT

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P4-P4-22-20

2017

Volltextzugriff (PDF)

Monitoring of Serum Her-2/neu Predicts Response and Progression-Free Survival to Trastuzumab-Based Treatment in Patients with Metastatic Breast Cancer

Clinical cancer research, 2004-03, Vol.10 (5), p.1618-1624

2004

Volltextzugriff (PDF)

Long-Term Outcomes of Adjuvant Denosumab in Breast Cancer

NEJM evidence, 2022-12, Vol.1 (12), p.EVIDoa2200162

2022

Volltextzugriff (PDF)

Abstract P2-08-17: Prognostic impact of breast cancer subtypes in elderly patients

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P2-P2-08-17

2016

Volltextzugriff (PDF)

Long-term persistence of acquired resistance to 5-fluorouracil in the colon cancer cell line SW620

Experimental cell research, 2010-11, Vol.316 (19), p.3172-3181

2010

Volltextzugriff (PDF)

PANTHER: Prospective randomized phase III trial of tailored and dose-dense versus standard tri-weekly adjuvant chemotherapy for high-risk breast cancer in the modern era of endocrine and anti-HER2 therapy

JOURNAL OF CLINICAL ONCOLOGY, 2016, Vol.34 (15_suppl), p.1002-1002

2016

Volltextzugriff (PDF)

Abstract S2-02: The impact of adjuvant denosumab on disease-free survival: Results from 3,425 postmenopausal patients of the ABCSG-18 trial

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.S2-S2-02

2016

Volltextzugriff (PDF)

Adjuvant denosumab in breast cancer: Results from 3,425 postmenopausal patients of the ABCSG-18 trial

JOURNAL OF CLINICAL ONCOLOGY, 2015, Vol.33 (15_suppl), p.504-504

2015

Volltextzugriff (PDF)

Abstract P1-08-40: BRCA-1 promotor methylation and p53 mutation in triple-negative breast cancer patients refrectory to taxane-based neoadjuvant chemotherapy

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P1-P1-08-40

2013

Volltextzugriff (PDF)

Abstract PD01-03: Review of Capecitabine for the Treatment of Triple-Negative Early Breast Cancer

Cancer research (Chicago, Ill.), 2010-12, Vol.70 (24_Supplement), p.PD01-03-PD01-03

2010

Volltextzugriff (PDF)

Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study

BMC cancer, 2006-03, Vol.6 (1), p.63-63, Article 63

2006

Volltextzugriff (PDF)

Expression of MRP1, LRP and PGP in breast carcinoma patients treated with preoperative chemotherapy

Breast cancer research and treatment, 2003-09, Vol.81 (2), p.149-157

2003

Volltextzugriff (PDF)

OT2-01-02: First-Line Bevacizumab in Combination with Capecitabine or Paclitaxel for HER2−Negative Locally Recurrent or Metastatic Breast Cancer (LR/MBC): A Randomized Phase III Trial

Cancer research (Chicago, Ill.), 2011-12, Vol.71 (24_Supplement), p.OT2-01-02-OT2-01-02

2011

Volltextzugriff (PDF)

Dissecting progressive stages of 5‐fluorouracil resistance in vitro using RNA expression profiling

International journal of cancer, 2004-11, Vol.112 (2), p.200-212

2004

Volltextzugriff (PDF)

Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment

British journal of cancer, 2003-09, Vol.89 (6), p.983-991

2003

Volltextzugriff (PDF)

Fulvestrant (‘Faslodex’) in pre-treated patients with advanced breast cancer: A single-centre experience

European journal of cancer (1990), 2005-11, Vol.41 (17), p.2655-2661

2005

Volltextzugriff (PDF)

1 – 25 von 99

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(91)
Mit Volltextzugriff
(87)

Publikationsform

Artikel
(92)
Tagungsberichte
(7)

Sprache

Englisch
(98)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(78)
Life Sciences & Biomedicine
(77)
Humans
(75)
Female
(54)
Oncology
(53)
Biological And Medical Sciences
(47)
Middle Aged
(47)
Medical Sciences
(46)
Adult
(39)
Aged
(37)
Pharmacology. Drug Treatments
(35)
Breast Neoplasms - Drug Therapy
(31)
Antineoplastic Agents
(27)
Male
(22)
Breast Cancer
(21)
Breast Neoplasms - Pathology
(20)
Chemotherapy
(20)
Treatment Outcome
(19)
Pharmacology & Pharmacy
(18)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(17)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial

Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: further results from the prospective PANTHER study with focus on obese patients

Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial

Phase II Genomics Study of Ixabepilone as Neoadjuvant Treatment for Breast Cancer

Abstract P6-21-02: Withdrawn

Tailored dose-dense chemotherapy in combination with trastuzumab as adjuvant therapy for HER2-positive breast cancer: A secondary analysis of the phase III PANTHER trial

Dose tailoring of breast cancer adjuvant chemotherapy aiming at avoiding both over and undertreatment: Results from the prospective PANTHER study

Adjuvant denosumab in early breast cancer: Disease-free survival analysis of 3,425 postmenopausal patients in the ABCSG-18 trial

Abstract P1-09-10: Pathological complete response to neoadjuvant trastuzumab is dependent on HER2/CEP17 ratio in HER2-amplified early breast cancer

Abstract P4-22-20: Efficacy and safety of everolimus plus exemestane in HR+, HER2– advanced breast cancer progressing on/after prior endocrine therapy, in routine clinical practice: 2nd interim analysis from STEPAUT

Monitoring of Serum Her-2/neu Predicts Response and Progression-Free Survival to Trastuzumab-Based Treatment in Patients with Metastatic Breast Cancer

Long-Term Outcomes of Adjuvant Denosumab in Breast Cancer

Abstract P2-08-17: Prognostic impact of breast cancer subtypes in elderly patients

Long-term persistence of acquired resistance to 5-fluorouracil in the colon cancer cell line SW620

PANTHER: Prospective randomized phase III trial of tailored and dose-dense versus standard tri-weekly adjuvant chemotherapy for high-risk breast cancer in the modern era of endocrine and anti-HER2 therapy

Abstract S2-02: The impact of adjuvant denosumab on disease-free survival: Results from 3,425 postmenopausal patients of the ABCSG-18 trial

Adjuvant denosumab in breast cancer: Results from 3,425 postmenopausal patients of the ABCSG-18 trial

Abstract P1-08-40: BRCA-1 promotor methylation and p53 mutation in triple-negative breast cancer patients refrectory to taxane-based neoadjuvant chemotherapy

Abstract PD01-03: Review of Capecitabine for the Treatment of Triple-Negative Early Breast Cancer

Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study

Expression of MRP1, LRP and PGP in breast carcinoma patients treated with preoperative chemotherapy

OT2-01-02: First-Line Bevacizumab in Combination with Capecitabine or Paclitaxel for HER2−Negative Locally Recurrent or Metastatic Breast Cancer (LR/MBC): A Randomized Phase III Trial

Dissecting progressive stages of 5‐fluorouracil resistance in vitro using RNA expression profiling

Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment

Fulvestrant (‘Faslodex’) in pre-treated patients with advanced breast cancer: A single-centre experience

Suchergebnisse filtern